References
  1. Sahu KK, Prakash G et al. A Rare Case of Haemorrhagic Cystitis in Allogeneic Haematopoetic Stem Cell Transplant Patient. Indian J of Haematology and Blood Transfusion 2016; 390: 196-200.
  2. Ebiloglu T, Kaya E, Yilmaz S, Özgür G, Kibar Y. Treatment of Resistant Cyclophosphamide Induced Haemorrhagic Cystitis: Review of Literature and Three Case Reports 2016; 10(4): 15-16.
  3. Payne H, Adamson A et al. Chemical and Radiation Induced Haemorrhagic Cystitis: Current Treatments and Challenges. BJU International 2013; 112(7): 885-897.
  4. Seber A, Shu XO, Defor T, Sencer S, Ramsay N. Risk Factors for Severe Haemorrhagic Cystitis Following BMT. Bone Marrow Transplantation. 1999. 23: 35-40.
  5. Decker DB, Karam JA, Wilcox DT. Paediatric Haemorrhagic Cystitis. Journal of Paediatric Urology 2009; 5: 254-264.
  6. Heath JA, Mishra S, Mitchell S, Waters KD, Tiedemann K. Estrogen as treatment of hemorrhagic cystitis in children and adolescents undergoing bone marrow transplantation . Bone Marrow Transplant 2006; 37: 523-26.
  7. Miller J, Burfield GD, Moretti KL. Oral conjugated estrogen therapy for treatment of haemorrhagic cystitis . J Urol 1994; 151: 1348.17.
  8. Mukamel E, Lupu A, deKernion JB. Alum irrigation for severe bladder hemorrhage . J Urol 1986; 135: 784.
  9. Au JK, Graziano C et al. Urologic Outcomes of Children with Haemorrhagic Cystitis After Bone Marrow Transplant at a Single Institution. Urology 2016; 101: 126-132.
  10. Duthie G, Whyte L, Chandran H, Lawson S, Velangi M, McCarthy L.Introduction of Sodium Pentosan Polysulphate and Avoidance of Urethral Catheterisation: Improved Outcomes in Children With Haemorrhagic Cystitis Post Stem Cell Transplant/Chemotherapy. J Paediatric Surgery 2012; 47(2): 375-9.
  11. Simerville JA, Maxted WC, Pahira JJ. Urinalysis: A Comprehensive Review. Am Fam Physician 2005; 71: 1153-1162.
  12. Hu J, Li S et al. Incidence, Risk Factors and the Effect of Polyoma Virus Infection in Haematopoetic Stem Cell Transplant Recipients. J International Medical Research 2017; 45(2): 762-770.
  13. Lynch JP, Fishbein M, Ecchavaria M. Adenovirus. Seminars in Respiratory and Critical Care Medicine 2011; 32(4): 494-511.
  14. Liu H, Chang JY. Proton Therapy in Clinical Practice. Chinese Journal of Cancer 2011; 30(5): 315-326.
  15. EMC. Vincristine Sulphate 1mg/ml for Injection. Authorised 2/12/2008. Accessed 10/12/2019 athttps://www.medicines.org.uk/emc/product/1502/smpc.
  16. EMC. Lomustine “Medac” 40mg. Authorised 25/08/2006. Accessed 10/12/2019 athttps://www.medicines.org.uk/emc/product/1401/smpc.
  17. Crona DJ, Faso A et al. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist 2017; 22(5): 609-619.
  18. Miller RP, Tadagavadhi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin Nephrotoxicity. Toxins 2010; 2(11): 2490-2518.
  19. Leonhauser D, Kranz J et al. Expression of Components of the Urothelial Cholinergic System in Bladder and Cultivated Primary Urothelial Cells of the Pig. BMC Urology 2019; 19: 62.
  20. Cantwell BM, Harris AL, Patrick D, Hall RR. Haemorrhagic Cystitis After I.V. Bleomycin, Vinblastine, Cisplatin and Etoposide for Testicular Cancer. Cancer Treatment Reports 1986; 70(4): 548-9.